United Therapeutics Insider Plans $3.1 M Stock Sale Under 10b5-1 Plan

Rhea-AI Filing Summary

United Therapeutics Corp. (UTHR) – Form 144 filing summary

Officer Paul A. Mahon has filed a Form 144 indicating his intent to sell 11,000 common shares of United Therapeutics on or after 26 Jun 2025 through Morgan Stanley Smith Barney. The shares have an estimated aggregate market value of $3.14 million. The company has 45.11 million shares outstanding, so the proposed sale represents roughly 0.024 % of shares outstanding.

Recent insider activity:

• During the past three months, Mahon has already sold 66,000 shares across seven transactions, generating $19.60 million in gross proceeds.
• If the newly-noticed 11,000-share tranche is executed, cumulative sales since 3 Apr 2025 will reach 77,000 shares (≈ 0.17 % of outstanding).

The filing cites a 10b5-1 trading plan adopted on 24 Dec 2024, and the signer affirms no undisclosed material adverse information. No other financial data or corporate developments are disclosed in this notice.

Key takeaways for investors:

• Continued insider selling by a senior officer may be interpreted as a modestly negative sentiment signal, though the percentage of total shares is small.
• The existence of a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading.
• No operational, earnings, or strategic information is included; the filing is strictly a regulatory notice of planned sales.

Positive

• None.

Negative

• Continued insider selling: Officer Paul Mahon has disposed of or plans to dispose of 77,000 shares within a three-month window, potentially signaling reduced insider confidence.

Insights

Senior Financial Analyst

TL;DR – Officer plans another 11k-share sale; cumulative 77k shares in three months; modestly negative sentiment but immaterial to float.

The Form 144 shows Paul Mahon’s intention to dispose of 11,000 UTHR shares (~$3.1 mn). Added to 66,000 shares already sold since April, insider liquidations total roughly 0.17 % of outstanding shares and ~$22.7 mn in proceeds. From a valuation standpoint, this selling volume is negligible relative to average daily trading volume and market capitalisation, so price impact should be limited. Nevertheless, persistent insider selling can weigh on sentiment, particularly given Mahon’s officer status. The presence of a 10b5-1 plan suggests the trades are pre-scheduled, reducing the risk of material-information misuse.

Corporate Governance Specialist

TL;DR – Continuous sales under 10b5-1 plan signal diversification, not control change; governance risk low.

Form 144 filings primarily serve transparency. This notice reaffirms that Mahon’s trades follow an adopted 10b5-1 plan (24 Dec 2024), aligning with best-practice governance. The cumulative stake sold remains well below Rule 144 volume limits (the lower of 1 % of shares outstanding or average weekly volume). There is no indication of broader board or executive departures, proxy contests, or control shifts. Consequently, I consider governance risk minimal; however, investors should continue monitoring insider filings for trend changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001231589
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	UNITED THERAPEUTICS CORPORATION
SEC File Number	000-26301
Address of Issuer	1000 SPRING STREET SILVER SPRING MARYLAND 20910
Phone	(301) 608-9292
Name of Person for Whose Account the Securities are To Be Sold	PAUL MAHON
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11000	3142717.60	45106623	06/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/26/2025	Stock Option Exercise	Issuer			11000	06/26/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	06/12/2025	11000	3079513.80
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/29/2025	4000	1263080.00
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/29/2025	7000	2213684.90
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/15/2025	11000	3246149.50
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/01/2025	11000	3310200.30
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	04/17/2025	11000	3121542.60
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	04/03/2025	11000	3367983.30

144: Remarks and Signature

Remarks
Date of Notice	06/26/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/24/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Paul A. Mahon
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many United Therapeutics (UTHR) shares is Officer Paul Mahon planning to sell under the new Form 144?

He intends to sell 11,000 common shares valued at about $3.14 million on or after 26 Jun 2025.

What percentage of United Therapeutics' outstanding shares does the planned 11,000-share sale represent?

Approximately 0.024 % of the company’s 45.11 million shares outstanding.

How many shares has Paul Mahon sold in the past three months prior to this notice?

He has sold 66,000 shares between 3 Apr 2025 and 12 Jun 2025, generating $19.6 million in gross proceeds.

Is the planned sale under a Rule 10b5-1 trading plan?

Yes. The filing states a 10b5-1 plan was adopted on 24 Dec 2024, indicating pre-scheduled transactions.

Does the Form 144 contain any operational or earnings information about UTHR?

No. Form 144 only notifies of proposed insider sales; it does not include operational, earnings, or strategic data.